Skip to main content

Table 2 Dose optimisation strategy for TNFi

From: Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial

TNFi

100%

66%

50%

0%

Adalimumab/Certolizumab

40 mg

14 days interval

40 mg

21 days interval

40 mg

28 days interval

Stop TNFi

Etanercept

50 mg

7 days interval

50 mg

10 days interval

50 mg

14 days interval

Stop TNFi

Golimumab

50 mg

4 weeks interval

50 mg

6 weeks interval

50 mg

8 weeks interval

Stop TNFi

Infliximab

5 mg/kg

8 weeks interval

3 mg/kg

8 weeks interval

3 mg/kg

8 weeks interval

2.25 mg/kg

8 weeks interval

1.5 mg/kg

8 weeks interval

1.5 mg/kg

8 weeks interval

Stop TNFi

  1. TNFi tumour necrosis factor inhibitor